Skip to search formSkip to main contentSkip to account menu

obatoclax

Known as: 1H-Indole, 2-(2-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-3-methoxy-2H-pyrrol-5-yl)- 
A small molecule and a pan-inhibitor of Bcl-2 family proteins, with pro-apoptotic activity. GX015-070 is a selective antagonist of the BH3-binding… 
National Institutes of Health

Related topics

Related topics

4 relations
Apoptosis Promoterobatoclax mesylate

Narrower (1)

GX 15-070

Broader (1)

Pyrroles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Sparse expression bases in cancer reveal tumor drivers
We define a new category of candidate tumor drivers in cancer genome evolution: ‘selected expression regulators’ (SERs)—genes… 
2014
2014
Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells
Interfering oncogenic STAT3 signaling is a promising anti-cancer strategy. We examined the efficacy and drug mechanism of an… 
2013
2013
Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells
The present studies were designed to compare and contrast the abilities of TRAIL (death receptor agonist) and obatoclax (BCL‐2… 
2012
2012
Lapatinib and Obatoclax Kill Tumor Cells through Blockade of ERBB1/3/4 and through Inhibition of BCL-xL and MCL-1
Prior studies in breast cancer cells have shown that lapatinib and obatoclax interact in a greater than additive fashion to cause… 
2011
2011
Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.
Small cell lung cancer (SCLC) is an aggressive disease in which, after initial sensitivity to platinum/etoposide chemotherapy… 
2011
2011
A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).
7001 Background: Ob is a pan-BCL-2 antagonist that is synergistic in vitro with cisplatin and E. A phase I study concluded that a… 
2011
2011
Obatoclax in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL
Abstract 2865 Obatoclax is a small molecule mimetic of the BH3 domain of Bcl-2 family proteins. Obatoclax is broadly specific… 
2009
2009
A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC).
3576 Background: Obatoclax (Ob) is a small-molecule antagonist of all the Bcl-2 prosurvival proteins. In vitro it enhances the… 
2009
2009
A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML).
3579 Background: Obatoclax (Ob) is a small-molecule inhibitor of all Bcl-2 prosurvival proteins. In a previous study a 70 year… 
2006
2006
Obatoclax (GX15-070) Is a Potent Antagonist of Constitutive Mcl-1/Bak Interactions in Intact Mitochondrial Membrane and Synergizes with Bortezomib in Mantle Cell Lymphoma.
Obatoclax (GX15-070), a synthetic small molecule pan-Bcl-2 family inhibitor, is currently under investigation in multiple Phase… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)